🇺🇸 FDA
Pipeline program

HY-2003 (10 mg/ml), BELKYRA and placebo

HY-2003-101

Phase 1 small_molecule active

Quick answer

HY-2003 (10 mg/ml), BELKYRA and placebo for Moderate or Severe Submental Fullness is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Moderate or Severe Submental Fullness
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials